Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01708278 · ClinicalTrials.gov registry record · Phase 1
Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01708278 is a Phase 1 study that has completed, run by University of Michigan. The registered enrollment target is 9 participants.
The verdict
NCT01708278, a Phase 1 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
Chronic obstructive pulmonary disease (COPD) is a progressive disorder of the lung parenchyma and airways, which is the third-leading cause of death in the USA. Current therapies for COPD are only partially effective and may also have side effects. Although increasing evidence indicates that quercetin supplementation may be beneficial in treating COPD, key methodological issues have not been resolved. The overall objective of this study is to determine the dosage of quercetin supplementation, bioavailability of quercetin, safety, dose-response relationship and appropriate biomarkers which reflect clinical outcomes in patients with COPD that is necessary for conducting large clinical trials in this patient population.
Interventions
- DRUG Quercetin
- OTHER Placebo - sugar chew
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01708278
The ClinicalTrials.gov registry entry for NCT01708278 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Quercetin is the first listed.
NCT01708278 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01708278 about?
NCT01708278 is a clinical study titled "Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)". Chronic obstructive pulmonary disease (COPD) is a progressive disorder of the lung parenchyma and airways, which is the third-leading cause of death in the USA. Current therapies for COPD are only partially effective and may also have side effects. Although increasing evidence indicates that quercet...
What is the current status of trial NCT01708278?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2014-02. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01708278?
The interventions under investigation include: Quercetin (DRUG), Placebo - sugar chew (OTHER).
Who is sponsoring clinical trial NCT01708278?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.